Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1358-1362

  Stevenson, J P ^a   Scher, R M ^b   Kosierowski, R ^c   Fox, S C ^c   Simmonds, M ^c   Yao, K S ^a   Green, F ^b   Broom, C ^d   Fields, S Z ^d   Krebs, J B ^d   O'Dwyer, P J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Fox Chase Center   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Continuous infusion; Pancreatic cancer; Phase II trial; Topotecan

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TOPOTECAN; TREATMENT OUTCOME;

EID: 0032146037     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00053-7     Document Type: Article

References (22)

1. 1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J Clin 1997, 47, 5-27.
2. 2. Evans DB, Abbruzzese JL, Rich TR. Cancer of the pancreas. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1997, 1054-1087.
3. 3. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads +5-fluorouracil), and high dose radiation +5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48, 1705-1710.
4. 4. Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 1988, 295, 91-93.
5. 5. Cullinan SA, Moertal CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985, 253, 2061-2067.
6. 6. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12, 29-34.
7. 7. Burris HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997, 15, 2403-2410.
8. 8. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992, 31, 229-239.
9. 9. Burris HA III, Hanauske A-R, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992, 84, 1816-1820.
10. 10. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I targeted chemotherapy of human colon cancer xenografts. Science 1989, 246, 1046-1048.
11. 11. Takimoto CH, Arbuck SG. The camptothecins. In Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia, Lippincott-Raven, 1996, 13, 463-484.
12. 12. Scher RM, Kosierowski R, Lusch C, et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996, 13, 347-354.
13. 13. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low dose continuous topotecan infusion in patients with cancer: an active and well tolerated regimen. J Clin Oncol 1994, 12, 553-559.
14. 14. National Cancer Institute. Guidelines for Reporting Adverse Drug Reactions. Bethesda, Maryland, Division of Cancer Treatment, National Cancer Institute, 1988.
15. 15. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva, World Health Organization, 1979.
16. 16. Kaplan E, Meier R. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
17. 17. Danks MK, Pawlik CA, Whipple DO, Wolveron JS. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin Cancer Res 1997, 3, 1731-1738.
18. 18. Creemers GJ, Gerrits CJH, Schellens JHM, et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996, 14, 2540-2545.
19. 19. Herben VMM, Ten Bokkel Huinink WW, Schot M, Hudson I, Beijnen JH. Continuous infusion of low-dose topotecan: a clinical pharmacologic phase II study in patients with small cell lung cancer. Proc Am Soc Clin Oncol 1997, 16, 238a.
20. 20. Hochster H, Chachoua A, Sorich J, et al. Phase I study of paclitaxel combined with 14-day topotecan continuous IV infusion in previously treated and untreated patients. Proc Am Soc Clin Oncol 1997, 16, 238a.
21. 21. Sugarman SM, Pazdur R, Daugherty K, et al. A phase II trial of topotecan for the treatment of unresectable pancreatic cancer. Proc Am Soc Clin Oncol 1994, 13, 224a.
22. 22. O'Reilly S, Donehower RG, Rowinsky EK, Ord S, Grochow LB. A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 1996, 7, 410-414.